RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Applied Therapeutics Stock

Applied Therapeutics ROE 2024

Applied Therapeutics ROE

6.98

Ticker

APLT

ISIN

US03828A1016

WKN

A2PHHB

In 2024, Applied Therapeutics's return on equity (ROE) was 6.98, a -134.71% increase from the -20.12 ROE in the previous year.

Applied Therapeutics Aktienanalyse

What does Applied Therapeutics do?

Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for chronic and specific serious diseases. The company was founded in 2016 by Shoshana Shendelman, who is also the CEO of the company. Applied Therapeutics is headquartered in New York City and currently employs over 50 employees. The business model of Applied Therapeutics is designed to address gaps in current medical care and develop novel therapies that do not yet exist. The company invests heavily in research and development to find new drugs and therapies that are more effective and safer than existing treatment methods. Applied Therapeutics has focused on developing drugs that can be used in the areas of neurological and cardiovascular diseases, as well as metabolic diseases. The main products currently under development aim to treat metabolic diseases such as diabetic neuropathy and mucopolysaccharidosis (MPS). The company has a broad portfolio of technologies, including the targeted protein degrader platform, which aims to degrade critical proteins that play a role in certain diseases. Applied Therapeutics also uses genomics to gain a deeper understanding of the underlying causes of diseases. By identifying targets for new drugs and therapies, the company also uses AI algorithms to select promising candidates for clinical trials. Applied Therapeutics' particular expertise lies in the research of molecules that play a key role in regulating carbohydrate metabolism and energy production in the body. Applied Therapeutics' medications aim to selectively regulate these critical molecules and thus combat various diseases. The first product from Applied Therapeutics is AT-001, a medication for the treatment of diabetic neuropathies. A phase II study has shown that AT-001 provides a significant improvement in neuropathic pain and sensitivity. The medication is currently being tested in a phase III clinical trial. Another promising class of drugs from Applied Therapeutics is the SGLT2 inhibitor, which targets carbohydrate metabolism and thus covers a wide range of diseases, from diabetes to cardiovascular diseases. Applied Therapeutics has also signed a license agreement with the University of Minnesota for the development of medications for the treatment of MPS I. In this collaboration, the company brings its expertise in molecules regulating carbohydrate and energy metabolism to develop a new treatment for MPS patients. It is important to mention that Applied Therapeutics' drugs are still in development and are in various stages of clinical trials. After completing the clinical trials and potential FDA approval, the products must also be brought to market, which can pose additional challenges. Overall, Applied Therapeutics has focused on developing therapies for chronic and serious diseases. The company has a broad portfolio of technologies aimed at combating the underlying causes of diseases. With AT-001 already on the market, the company has brought a promising medication to market, and additional products are in development. Whether the company will meet its ambitious goals remains to be seen, but there is no doubt that it operates in an exciting area with great potential. Applied Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Applied Therapeutics's Return on Equity (ROE)

Applied Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Applied Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Applied Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Applied Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Applied Therapeutics stock

What is the ROE (Return on Equity) of Applied Therapeutics this year?

The ROE of Applied Therapeutics this year is 6.98 undefined.

How has the Return on Equity (ROE) of Applied Therapeutics developed compared to the previous year?

The ROE of Applied Therapeutics has increased by -134.71% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Applied Therapeutics?

A high ROE indicates that Applied Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Applied Therapeutics?

A low ROE can indicate that Applied Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Applied Therapeutics affect the company?

A change in ROE (Return on Equity) of Applied Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Applied Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Applied Therapeutics?

Some factors that can influence Applied Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Applied Therapeutics pay?

Over the past 12 months, Applied Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Applied Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Applied Therapeutics?

The current dividend yield of Applied Therapeutics is .

When does Applied Therapeutics pay dividends?

Applied Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Applied Therapeutics?

Applied Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Applied Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Applied Therapeutics located?

Applied Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Applied Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Applied Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Applied Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Applied Therapeutics in the year 2023?

In the year 2023, Applied Therapeutics distributed 0 USD as dividends.

In which currency does Applied Therapeutics pay out the dividend?

The dividends of Applied Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Applied Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Applied Therapeutics

Our stock analysis for Applied Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.